Devices

A muscle-mediated peripheral nerve interface (RPNI) used as a biological signal amplifier: reinnervated muscle grafts generate stable, high-SNR EMG for long-term prosthetic control without chronic intraneural electrodes.

Device — Peripheral nerve

TEENI-RPNI (tissue-engineered electronic nerve interface – regenerative peripheral nerve interface)

Official site →

PNI · RPNI · TEENI · biohybrid · EMG · amputation · prosthetic control · neuroma prevention · peripheral nerve · recording · stimulation · bidirectional · regenerative

TEENI-RPNI (tissue-engineered electronic nerve interface – regenerative peripheral nerve interface)

One-line verdict: A biological neural amplifier that converts peripheral nerve efferent activity into stable, high-SNR EMG by reinnervating a free muscle graft, enabling long-term control without chronic intraneural electrodes.

Quick tags: Recording (EMG) · Stimulation (not primary) · Species: Human · Status: early translation / research

Overview

What it is: A regenerative peripheral nerve interface (RPNI) is a bio-hybrid construct where a transected peripheral nerve end is implanted into a free (devascularized) muscle graft. The graft revascularizes and becomes reinnervated, producing EMG signals that can be recorded with standard intramuscular or epimysial electrodes.

Why it matters: Instead of putting an electrode at the nerve (and fighting micromotion, fibrosis, and chronic stability), an RPNI uses biology to do the transduction and amplification. EMG is large-amplitude and robust relative to CAP-scale nerve recordings, making it attractive for long-term prosthetic control.

Most comparable devices: intraneural electrodes (LIFE/TIME/USEA) for higher selectivity but harder chronic stability; extraneural cuffs (spiral/FINE) for lower risk but lower selectivity; targeted muscle reinnervation (TMR) as another signal acquisition pathway.

Spec Card Grid

Identity

  • Device name: TEENI-RPNI
  • Canonical ID: BTSD-PNI-0010
  • Key lineage: RPNI program (Cederna / Kung / Urbanchek and collaborators)
  • Org / manufacturer: academic translational programs (construct + electrode system are program-dependent)
  • First demonstrated (year): preclinical demonstrations in the 2010s; ongoing human translation through the 2020s
  • First implanted (year): human RPNI surgeries reported in the 2010s–2020s (program-dependent)
  • Species: human
  • Regulatory / trial status: research / early translation (study-dependent)
  • Primary use: recording (EMG for control)
  • Primary target: transected peripheral motor nerves (amputation context)

Geometry & Architecture

  • Interface type: regenerative, muscle-mediated PNI
  • Penetrating neural tissue: no (electrode interfaces with muscle; nerve is implanted into graft)
  • Surgical construct: free muscle graft (size varies by target anatomy and program)
  • Electrode placement: intramuscular or epimysial electrodes embedded in/over the graft
  • Anchoring method: biological integration (revascularization + reinnervation) + lead strain relief
  • Mechanical compliance: native tissue compliance (high)

Electrode & Channel Physics

  • Neural transduction: nerve action potentials → motor unit activation → EMG
  • Channel count: 1–multiple EMG channels per RPNI (depends on electrode placement); multiple RPNIs can be implanted
  • Signal type: EMG (high amplitude, low impedance relative to nerve microelectrodes)
  • SNR: high in reported human work (see references)
  • Stimulation capability: possible but not the core purpose in most RPNI control work

Tissue Interface & Bioresponse

  • Target tissue for electrodes: skeletal muscle (reinnervated)
  • Foreign-body response: occurs primarily at electrode–muscle interface, not at a chronic nerve–electrode boundary
  • Micromotion sensitivity: lower than intraneural electrodes (muscle is mechanically forgiving)
  • Nerve health considerations: RPNI is also used as a strategy to mitigate neuroma formation and post-amputation pain (program-dependent)
  • Failure modes: muscle atrophy or poor reinnervation; lead/electrode failures; infection (system-dependent)

System Architecture

  • Electronics location: external or implanted (system-dependent)
  • Data path: EMG → amplifier → decoder → prosthetic control
  • Telemetry: optional (system-dependent)
  • Hermeticity: not required at the nerve interface itself; depends on any implanted electronics

Performance Envelope

  • Signal stability: multi-year-class stability reported in human participants in the literature
  • Control fidelity: supports multi-DOF prosthetic control in published work
  • Latency: physiologic motor-unit timescale
  • Scaling constraints: surgical footprint (multiple grafts take space) and complexity scale with channel count

Clinical / Preclinical Evidence

  • Human evidence: implanted EMG electrodes in RPNIs used for long-term upper-extremity prosthetic control in humans (see references)
  • Key limitations: heterogeneous implementations (graft size, electrode type, decoding pipeline) mean performance should be tied to specific studies

Engineering Verdict

Strengths:

  • avoids chronic nerve-electrode failure modes
  • high-SNR signals without intraneural penetration
  • biologically self-maintaining interface when reinnervation is successful

Limitations / failure modes:

  • requires transection/amputation context for typical deployment
  • bandwidth is EMG-limited (not single-unit)
  • less direct for pure sensory afferent recording

References

  • Vu PP, Vaskov AK, Lee C, et al. Long-term upper-extremity prosthetic control using regenerative peripheral nerve interfaces and implanted EMG electrodes. J Neural Eng. 2023;20(2):026039. doi: 10.1088/1741-2552/accb0c. PubMed: https://pubmed.ncbi.nlm.nih.gov/37023743/
  • Frost CM, et al. Regenerative peripheral nerve interfaces for real-time, proportional control of a neuroprosthetic hand. J Neuroeng Rehabil. 2018;15(1):108. doi: 10.1186/s12984-018-0452-1. PubMed: https://pubmed.ncbi.nlm.nih.gov/30458876/